Drug Information

Drug (ID: DG01489) and It's Reported Resistant Information

• Name: PD-180970
• Synonyms: 287204-45-9; PD180970; PD-180970; PD 180970; UNII-TSO2IAD7WJ; TSO2IAD7WJ; 6-(2,6-Dichlorophenyl)-2-[(4-fluoro-3-methylphenyl)amino]-8-methyl-pyrido[2,3-d]pyrimidin-7(8H)-one; 6-(2,6-DICHLORO-PHENYL)-2-(4-FLUORO-3-METHYL-PHENYLAMINO)-8-METHYL-8H-PYRIDO[2,3-D]PYRIMIDIN-7-ONE; 6-(2,6-Dichlorophenyl)-2-[(4-Fluoro-3-Methylphenyl)amino]-8-Methylpyrido[2,3-D]pyrimidin-7(8h)-One; 2hzi; 6-(2,6-Dichlorophenyl)-2-((4-fluoro-3-methylphenyl)amino)-8-methylpyrido(2,3-d)pyrimidin-7(8H)-one; 6-(2,6-dichlorophenyl)-2-((4-fluoro-3-methylphenyl)amino)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one; PD-180790; PD-0180970; PF-1515965; SCHEMBL256711; BDBM6572; CHEMBL574058; DTXSID90415508; ZINC602675; MFCD10565929; AKOS024458440; CCG-221312; 6-(2,6-dichlorophenyl)-2-(4-fluoro-3-methylanilino)-8-methylpyrido[2,3-d]pyrimidin-7-one; NCGC00379241-02; Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-((4-fluoro-3-methylphenyl)amino)-8-methyl-; HY-103274; CS-0026795; FT-0765936; PD-180970, >=98% (HPLC); J-017220; Q27290258; 6-(2,6-dichlorophenyl)-2-[(4-fluoro-3-methylphenyl)amino]-8-methyl-7H,8H-pyrido[2,3-d]pyrimidin-7-one; JIN
• Indication:
  In total 1 Indication(s)
  Diabetic complication [ICD-11: 5A2Y]; Investigative; [1]
• Target: Oxytocin receptor (OTR); OXYR_HUMAN; [1]
• Target: Vasopressin receptor (VR); NOUNIPROTAC; [1]
• Target: Vasopressin V1a receptor (V1AR); V1AR_HUMAN; [1]
• Target: Vasopressin V1b receptor (V1BR); V1BR_HUMAN; [1]
• Target: Vasopressin V2 receptor (V2R); V2R_HUMAN; [1]
• Formula: 3
• IsoSMILES: CC1=C(C=CC(=C1)NC2=NC=C3C=C(C(=O)N(C3=N2)C)C4=C(C=CC=C4Cl)Cl)F
• InChI: InChI=1S/C21H15Cl2FN4O/c1-11-8-13(6-7-17(11)24)26-21-25-10-12-9-14(20(29)28(2)19(12)27-21)18-15(22)4-3-5-16(18)23/h3-10H,1-2H3,(H,25,26,27)
• InChIKey: SLCFEJAMCRLYRG-UHFFFAOYSA-N
• PubChem CID: 5311104
• TTD Drug ID: D0U7SH

Type(s) of Resistant Mechanism of This Drug

  UAPP: Unusual Activation of Pro-survival Pathway

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Solid tumour/cancer [ICD-11: 2A00-2F9Z]

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Unusual Activation of Pro-survival Pathway (UAPP)

Key Molecule: Mast/stem cell growth factor receptor Kit (KIT) [1]

• Molecule Alteration: Missense mutation; p.V559D (c.1676T>A)
• Sensitive Disease: Solid tumour/cancer [ICD-11: 2A00-2F9Z]
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: HEK 293 cells; Kidney; Homo sapiens (Human); CVCL_0045
• Experiment for Molecule Alteration: ELISA assay
• Mechanism Description: The missense mutation p.V559D (c.1676T>A) in gene KIT cause the sensitivity of PD-180970 by unusual activation of pro-survival pathway

References

• Ref 1: Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinasesProc Natl Acad Sci U S A. 2005 Aug 2;102(31):11011-6. doi: 10.1073/pnas.0504952102. Epub 2005 Jul 26.